Roche bags 'breakthrough' anti-fibrosis drug in $1.4B biotech buyout deal
Roche is snapping up a “breakthrough” anti-fibrotic drug in a $1.4 billion buyout.
The pharma giant announced Friday that it is acquiring Promedior, primarily to get its hands on PRM-151, a recombinant form of human pentraxin-2 (PTX-2) protein that has nailed down mid-stage clinical data on idiopathic pulmonary fibrosis and demonstrating its potential for a range of fibrotic conditions.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.